Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease
The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages 1325–1332, https://doi.org/10.1210/clinem/dgab070
Published: 09 February 2021
Abstract
Context/objective
The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD).
Methods